Get the Stockscreener App
1,059.70
1.57%
16.41
After Hours:
1059.80
0.10
+0.01%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,059.70, with a volume of 4.14M.
It is up +1.57% in the last 24 hours and up +32.53% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,043.29
Open:
$1041
24h Volume:
4.14M
Relative Volume:
1.10
Market Cap:
$1.00T
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.41
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+3.36%
1M Performance:
+32.53%
6M Performance:
+46.18%
1Y Performance:
+41.31%
1-Day Range:
$1,038.00
$1,066.65
1-Week Range:
$998.30
$1,066.65
52-Week Range:
$623.78
$1,066.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,059.70 | 933.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.90 | 489.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
236.28 | 405.53B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
127.31 | 238.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.76 | 235.72B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Driehaus Capital Reduces Stake in Eli Lilly - TipRanks
Coatue Management Reduces Stake in Eli Lilly - TipRanks
Maverick Capital Ltd Reduces Stake in Eli Lilly - TipRanks
Bridgewater Associates Boosts Stake in Eli Lilly - TipRanks
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? - AOL.com
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? - The Motley Fool
Eli Lilly Stock Price ForecastLLY Shares Hits $1T Market as GLP-1 Sales Surge 54% and EPS Jumps 495% - TradingNEWS
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 - Seeking Alpha
Eli Lilly Stock Value Tops $1 Trillion. Learn Why And If To Buy $LLY - Forbes
Eli Lilly’s Market Cap Breaks $1 Trillion After Climbing $400 Billion in 3 Months - MSN
Eli Lilly's market capitalization hits $1 trillion - MarketScreener
Eli Lilly and Company Stock (LLY) Opinions on $1 Trillion Market Cap Milestone - Quiver Quantitative
Dow Jones Futures: Stocks Bounce, But Wait For This; Nvidia, Apple, Eli Lilly In Focus - Investor's Business Daily
Eli Lilly joins trillion-dollar club, fueled by weight loss drug demand boom - Medical Dialogues
Why Eli Lilly Stock Jumped 50%? - Trefis
Eli Lilly: The Weight-Loss Leader With More Upside If Execution Holds - Seeking Alpha
Eli Lilly reaches $1 trillion in value - Hawaii Tribune-Herald
When Investors Panic, I Buy Eli Lilly Stock (NYSE:LLY) - Seeking Alpha
Eli Lilly Hits $1 Trillion—But 2026 Wild Ride Awaits: 20% Steady Gains or 100% Moonshot? - FXLeaders
Eli Lilly Pharmaceutical Makes History: First Ever Pharmaceutical Company to Hit $1 Trillion Market Valuation - BioTecNika
Eli Lilly hits $1 trillion market value as weight-loss drugs soar - Aaj English TV
Weight-loss drugs lead to hefty gains as Eli Lilly hits $1tr market capitalisation - Arabian Business
Eli Lilly hits trillion dollar market cap - Morning Brew
LLY News Today, Nov 22: Eli Lilly Joins the Trillion-Dollar Club - Meyka
Eli Lilly hit $1 trillion, propelled by weight-loss drug boom - qz.com
Major Shareholder Cashes Out Millions in Eli Lilly Stock! - TipRanks
Eli Lilly Joins US$1 Trillion Club As Weight-Loss Drugs Power Market Surge - BusinessToday Malaysia
Eli Lilly and Company (LLY) Welcomes New Board Member - GuruFocus
Mounjaro maker Eli Lilly swells to $1trillion - MSN
Eli Lilly appoints Carolyn Bertozzi to board of directors effective December - Investing.com Canada
U.S. Stock Market Close | Major indices rebound collectively, Nasdaq once surged over 2%; Google hits record closing high; Eli Lilly and Co becomes the first pharmaceutical company with a market value of one trillion U.S. dollars; Oracle records sixth con - 富途牛牛
Eli Lilly becomes first healthcare company to reach $1 trillion market value - The American Bazaar
The Score: Nvidia, Constellation, Eli Lilly, Gap and More Stocks That Defined the Week - MSN
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand - MSN
Eli Lilly Joins The Trillion-Dollar Club, Outpacing Big Tech - Finimize
Dow Jones Futures: Stocks Bounce, Still Battered; Nvidia, Apple, Eli Lilly In Focus - MSN
How Eli Lilly Became the First Pharma Company to Reach a $1 Trillion Market CapWhat’s NewsWSJ Podcasts - The Wall Street Journal
Eli Lilly Announces New Board Member Election - TipRanks
Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club - Investor's Business Daily
Lilly elects Stanford chemistry professor to board of directors - StreetInsider
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value - The New York Times
Eli Lilly & Co Appoints New Board Member - TradingView
Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here? - Barchart.com
Eli Lilly Becomes First Health-Care Company To Hit $1 Tln Market Value - Nasdaq
Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts - Reuters
The Eli Lilly compnay hits $1 trillion in market value - Reuters Connect
Eli Lilly joins the $1 trillion club - Axios
Eli Lilly becomes first healthcare company to hit $1 trillion - Fast Company
Eli Lilly Stock Is Rising Today: Here's What You Need To Know - Benzinga
Eli Lilly Joins Tech Players In The $1T Market Capitalization Club - Stocktwits
Eli Lilly 1st health company to hit $1 trillion in value - MSN
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):